Site Editor



FDA Approves Durvalumab in Combination Regimen for Advanced or Metastatic Biliary Tract Cancer

By: JNCCN 360 Staff
Posted: Friday, September 30, 2022

On September 2, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor durvalumab (Imfinzi) in combination with gemcitabine and cisplatin for adults with locally advanced or metastatic biliary tract cancer. Efficacy was evaluated in the phase III TOPAZ-1 trial ( identifier NCT03875235). This randomized, double-blind, placebo-controlled, multiregional study enrolled 685 patients with histologically confirmed locally advanced unresectable or metastatic biliary tract cancer who had not previously received systemic therapy for advanced disease.

In TOPAZ-1, 56% of patients had intrahepatic cholangiocarcinoma, 25% had gallbladder cancer, and 19% had extrahepatic cholangiocarcinoma. Patients were randomly assigned 1:1 to receive one of two regimens: durvalumab plus gemcitabine and cisplatin, followed by durvalumab, or placebo plus gemcitabine and cisplatin, followed by placebo.

The major efficacy outcome measure was overall survival. A statistically significant improvement in overall survival was demonstrated with durvalumab vs placebo. Median overall survival was 12.8 months (95% confidence interval [CI] = 11.1–14) months and 11.5 months (95% CI = 10.1–12.5 months) with durvalumab and placebo, respectively (hazard ratio = 0.80; 95% CI = 0.66–0.97, P = .021). The median progression-free survival was 7.2 months (95% CI = 6.7–7.4 months) and 5.7 months (95% CI = 5.6–6.7 months) with durvalumab and placebo, respectively. Investigator-assessed overall response rate was 27% (95% CI = 22%–32%) and 19% (95% CI = 15%–23%) in the durvalumab and placebo arms, respectively.

The most common (≥ 20%) adverse reactions occurring in patients were fatigue, nausea, constipation, decreased appetite, abdominal pain, rash, and pyrexia.

The recommended durvalumab dose is 1,500 mg every 3 weeks for patients with a body weight ≥ 30 kg when given with gemcitabine and cisplatin, followed by 1,500 mg every 4 weeks as a single agent until disease progression or unacceptable toxicity. For patients with a body weight < 30 kg, the recommended dose is 20 mg/kg every 3 weeks with gemcitabine and cisplatin followed by 20 mg/kg every 4 weeks until disease progression or unacceptable toxicity.

For more information on durvalumab, view the full prescribing information.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.